NCT02045368 - Study of Insulin-like Growth Factor (IGF)-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing IGF-1R | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 28, 2014

Primary Completion Date

September 30, 2016

Study Completion Date

September 30, 2016

Conditions

Breast CancerBrain CancerGastrointestinal CancersGenitourinary CancersGynecologic CancersHead and Neck CancersMelanomaThoracic Cancers

Interventions

DRUG

IGF-Methotrexate conjugate

IV infusion at the assigned dose administered on days 1, 8, and 15 of a 28 day (4 week) cycle. Up to 7 dose levels will be tested, starting with 0.05 microequivalents per kg and up to 2.5 microequivalents per kg.

Trial Locations (1)

60612

University of Illinois at Chicago, Chicago